The carnage in the stockmarkets has dragged some great small companies down with it. Benitec is a truly innovative company at the cutting edge in the biotech sector. We have already done very well with this stock. But for those of you that missed the first time around, this is a great opportunity to buy the stock at a bargain price. Check out our initial report dated 28th October 2006, for all the details. Below is an update printed in the Australian from 9th January 2008. This is an exciting development for Benitec and if the stock markets had not corrected this month, I think we would have seen this stock move much higher!
The Australian --- Page: 27
Pharmaceutical giant Pfizer has secured the international rights to a compound that is intended to treat hepatitis C. Pfizer has entered a licencing arrangement with Tacere Therapeutics to commercialise the TT-033 compound, whichf eatures three RNA interference (RNAi) elements. Tacere in turn had previously licensed the RNAi technology from Australian-listed Benitec, which still holds the rights to human therapeutic applications of the technology. Benitec shares closed $A0.075 higher at $A0.18 on 8 January 2008
Disclaimer: All the information above is provided as a service for individuals and institutions. It should in no way be construed as a recommendation as an investment. Investment decisions should be based on the risk tolerance and planning horizon of the investor. Market participants must understand that past performance is also not a guarantee or predictor of future results.